A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

NCT06503250 · clinicaltrials.gov ↗

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
RADIATION: Transarterial Chemoembolization

Sponsor

Hoffmann-La Roche